ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Warns of Liver Injury with Mavyret, Zepatier, Vosevi americanpharmaceuticalreview
September 03, 2019The Food and Drug Administration (FDA) has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases... -
FDA approves Vosevi for Hepatitis C
worldpharmanews
July 20, 2017The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.
Pharma Sources Insight January 2025
